Skip to content

Study · Randomized controlled trial · n = 260 · 2026

6 results

Tirzepatide therapy reduces subclinical leaflet thrombosis and paravalvular leak after transcatheter aortic valve replacement in obese patients: The TAVR-MET trial.

Thirugnanam AM, Chandrakanth, Pruthvi

Cardiovascular revascularization medicine : including molecular interventions23 Mar 2026

PMID42000295 (opens in a new tab)DOI10.1016/j.carrev.2026.03.011 (opens in a new tab)PepBankPUB-42000295
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In obese patients undergoing TAVR, tirzepatide reduced HALT incidence at 6 months (8.4% vs 21.6%) versus standard care.

    In plain wordsIn obese patients having a heart valve replacement, tirzepatide led to fewer valve leaflet clots at 6 months than standard care.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHALT incidence at 6 months
    Study

    n = 260

    Comparator
    Standard care
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    HALT incidence
    8.4%
    tirzepatide
    HALT incidence
    21.6%
    standard care

    Source sentences

    Summary
    Among 260 randomized patients, tirzepatide therapy significantly reduced HALT incidence (8.4% vs 21.6%, p = 0.002) and ≥ mild PVL (10.7% vs 25.3%, p = 0.006) at 6 months.
    2 context sentences
    Summary · context
    TAVR-MET was a prospective, randomized, open-label, multicenter trial enrolling obese patients (BMI ≥ 30 kg/m2) undergoing transfemoral TAVR.
    Summary · context
    Patients were randomized to tirzepatide therapy or standard care.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In obese patients undergoing TAVR, tirzepatide reduced paravalvular leak of mild grade or worse (10.7% vs 25.3%) versus standard care at 6 months.

    In plain wordsIn obese patients having a heart valve replacement, tirzepatide led to fewer valve leaks at 6 months than standard care.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMild or worse paravalvular leak at 6 months
    Study

    n = 260

    Comparator
    Standard care
    Analysis
    Secondary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    PVL of mild grade or worse
    10.7%
    tirzepatide
    PVL of mild grade or worse
    25.3%
    standard care

    Source sentences

    Summary
    Among 260 randomized patients, tirzepatide therapy significantly reduced HALT incidence (8.4% vs 21.6%, p = 0.002) and ≥ mild PVL (10.7% vs 25.3%, p = 0.006) at 6 months.
    2 context sentences
    Summary · context
    TAVR-MET was a prospective, randomized, open-label, multicenter trial enrolling obese patients (BMI ≥ 30 kg/m2) undergoing transfemoral TAVR.
    Summary · context
    Patients were randomized to tirzepatide therapy or standard care.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In obese patients undergoing TAVR, tirzepatide was associated with marked reductions in CRP.

    In plain wordsIn obese patients having a heart valve replacement, tirzepatide was linked to a clear drop in the inflammation marker CRP.

    Peptide
    Tirzepatide
    Outcome
    DecreaseCRP reduction
    Study

    n = 260

    Comparator
    Standard care
    Analysis
    Secondary
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Tirzepatide was associated with marked reductions in CRP
    2 context sentences
    Summary · context
    TAVR-MET was a prospective, randomized, open-label, multicenter trial enrolling obese patients (BMI ≥ 30 kg/m2) undergoing transfemoral TAVR.
    Summary · context
    Patients were randomized to tirzepatide therapy or standard care.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In obese patients undergoing TAVR, tirzepatide was associated with marked reductions in body weight.

    In plain wordsIn obese patients having a heart valve replacement, tirzepatide was linked to a clear drop in body weight.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight reduction
    Study

    n = 260

    Comparator
    Standard care
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Tirzepatide was associated with marked reductions in CRP and body weight
    2 context sentences
    Summary · context
    TAVR-MET was a prospective, randomized, open-label, multicenter trial enrolling obese patients (BMI ≥ 30 kg/m2) undergoing transfemoral TAVR.
    Summary · context
    Patients were randomized to tirzepatide therapy or standard care.
  5. 05HumanRandomized controlled trialSafety outcome

    In obese patients undergoing TAVR, tirzepatide was not associated with an increase in major bleeding.

    In plain wordsIn obese patients having a heart valve replacement, tirzepatide did not raise major bleeding.

    Peptide
    Tirzepatide
    Outcome
    No significant changeMajor bleeding
    Study

    n = 260

    Comparator
    Standard care
    Analysis
    Secondary
    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    without an increase in major bleeding.
    2 context sentences
    Summary · context
    TAVR-MET was a prospective, randomized, open-label, multicenter trial enrolling obese patients (BMI ≥ 30 kg/m2) undergoing transfemoral TAVR.
    Summary · context
    Patients were randomized to tirzepatide therapy or standard care.
  6. 06HumanRandomized controlled trialSafety outcome

    In obese patients undergoing TAVR, tirzepatide was not accompanied by adverse safety signals.

    In plain wordsIn obese patients having a heart valve replacement, no adverse safety signals were reported with tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    No significant changeAdverse safety signals
    Study

    n = 260

    Comparator
    Standard care
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    without an increase in major bleeding or adverse safety signals.
    2 context sentences
    Summary · context
    TAVR-MET was a prospective, randomized, open-label, multicenter trial enrolling obese patients (BMI ≥ 30 kg/m2) undergoing transfemoral TAVR.
    Summary · context
    Patients were randomized to tirzepatide therapy or standard care.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.